Can reimbursement unlock the next wave of office-based cancer care? What ZUSDURI and CMS J-codes reveal about oncology’s outpatient shift
Can J-codes like ZUSDURI’s drive the next wave of office-based cancer care? Find out why 2026 could be a turning point in outpatient oncology. Read More
Will UroGen Pharma’s reimbursement tailwind in 2026 turn ZUSDURI into a category-defining cancer therapy?
UroGen Pharma sets $1B peak sales goal for ZUSDURI as permanent J-code from 2026 is expected to drive widespread adoption in outpatient urology settings. Read More
Padcev and Keytruda combo cuts bladder cancer recurrence risk by 60% in pivotal Phase 3 win
Discover how the Padcev and Keytruda combination achieved unprecedented survival gains in bladder cancer — read our expert take. Read More
Why Japan’s review of Ferring’s bladder cancer gene therapy candidate could reshape urology
Discover how Ferring’s gene therapy nadofaragene firadenovec could transform NMIBC treatment in Japan after PMDA NDA acceptance. Read More
Photocure’s blue light cystoscopy demonstrates 38% recurrence reduction in BRAVO study
Photocure ASA, a bladder cancer company, has unveiled new clinical evidence demonstrating the advantages of blue light cystoscopy (BLC) over traditional white light cystoscopy (WLC) ... Read More
Blue Light cystoscopy enhances bladder cancer detection and upstaging at ASCO GU 2025
Bladder cancer remains one of the most prevalent and recurrent malignancies worldwide, requiring ongoing advancements in diagnostic and treatment strategies. At the 2025 American Society ... Read More
Unilabs partners with Pangea to bring advanced bladder cancer test to Switzerland
Pangea Laboratory and Unilabs have announced a strategic collaboration to introduce the Bladder CARE Assay, an advanced non-invasive diagnostic tool for early detection of bladder ... Read More
Japan’s MHLW grants priority review for PADCEV and KEYTRUDA combo in urothelial cancer
In a significant development in the fight against urothelial cancer, Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has awarded ... Read More
Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More
Ferring Pharmaceuticals begins treatment of first US patient with ADSTILADRIN
Ferring Pharmaceuticals has announced that the first patient in the United States suffering from high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) has been ... Read More